Kimball Electronics: The Medical CDMO Bet
The Strategic Pivot
Kimball Electronics' fiscal 2026 fourth-quarter report was more about positioning than performance. Sales of $371.6 million were down 2% year-over-year, but the real story was the company's aggressive pivot into the CDMO strategy — a move that now includes the letter "D" for development. As CEO Ric Phillips put it, “The addition of Helvoet has given us reason to reconsider how we talk about our Medical business... we're now incorporating the letter D in our reference to the Medical CDMO business.” — Richard Phillips, Chief Executive Officer · 2026-08-13 The acquisition of Helvoet, closed on July 1, adds precision polymer expertise and a European/Indian footprint, while the new facility in Indianapolis provides the U.S. cleanroom capacity that customers are demanding. Management emphasized that the two assets together will drive significant revenue synergies, though CFO Jana Croom was careful to guide that the ramp would be measured: "We wouldn't expect you'll see a big impact in '27 from Indianapolis just because new programs take time to ramp."
The financial commitment is visible in the numbers. The company ended fiscal 2026 with net debt of $113 million, down from a peak of $281 million in 2023, and the balance sheet is the enabler for this strategy. Jana Croom noted the company now has "plenty of dry powder in the form of borrowing capacity and available cash to strategically invest" — a phrase that has become a recurring theme in the company's earnings calls. In Q&A, she confirmed the target leverage range: "somewhere between 1.5 and 2x feels good for our business."
Balance Sheet and Working Capital
The cash conversion story is equally compelling. Cash conversion days fell to 82, the best in 17 quarters, with all components improving. This is not accidental; it's a deliberate operational discipline that has been building for several quarters. On the prior call, Croom had remarked, “we've done a lot to wring out the excess inventory in the balance sheet and improve working capital” — Jana Croom, Chief Financial Officer · 2025-11-06 — and that progress continued. However, she also warned that growth will require reinvestment: "We are planning for it to rise a few days in FY '27" as customers ask KE to carry more inventory in a supply chain that is seeing "golden screw type events."
The gross margin story is a double-edged sword. Q4 gross margin improved 90 basis points to 8.9% on favorable mix, but the company's overall margin is still in the mid-single digits. The new Indianapolis facility and the Helvoet acquisition are expected to be accretive over time, but near-term there is a drag. Croom quantified it on the call: "The drag from Indianapolis is probably closer to $6.5 million, $7 million, all in." She also confirmed that the previous guidance of a 40-50 basis point fiscal 2027 impact is still on track — a point she had made in May: “We expect a 40 to 50 basis point impact to gross margin in fiscal '27 related to the costs associated with ramping that facility.” — Jana Croom, Chief Financial Officer · 2026-05-06
Taxes and Guidance
The fourth quarter was also notable for a tax rate surge to 67.8%, driven by the resolution of dividend withholding matters at international locations. This depressed adjusted net income to a small loss per share, but management was quick to note that the rate is expected to normalize in the low 30s for fiscal 2027. As Jana Croom explained, “The effective tax rate in Q4 was 67.8% compared to 48.3% last year, with this year's rate adversely impacted by the resolution of two long-standing dividend withholding matters.” — Jana Croom, Chief Financial Officer · 2026-08-13 This is a one-time event, but it masks the underlying operating leverage.
Looking forward, fiscal 2027 guidance calls for revenue of $1.535–1.56 billion, implying 7–9% growth, with organic sales growth of 3–5% and $60 million from Helvoet. Adjusted operating income is guided to 4.4–4.7% of sales, a modest improvement from 4.6% in fiscal 2026, reflecting balanced growth across verticals. Medical is expected to approach 35% of total sales, up from 29% in Q4, while Automotive stabilizes and Industrial grows in line.
Stock Context and Valuation
Despite the strategic progress, the stock has not participated. The full chart shows a 30% drawdown from a September 2025 peak, and the recent 90-day trend is down 11%. The valuation, however, is modest — the stock trades at 0.4x trailing sales and 21.9x trailing net income — pricing in skepticism that the CDMO pivot will deliver. Investors will be watching whether the medical segment can sustain its double-digit growth and whether Helvoet integration delivers the promised synergies.
We believe this strategy will be powerful in driving value creation. Our strategic journey continues to build and so does my excitement for the future of the company.
The company is no longer just an EMS provider; it is becoming a specialized medical contract development and manufacturing organization. The dry powder on the balance sheet gives it the flexibility to pursue additional tuck-ins, but the immediate focus is on execution. If the organic growth in medical materializes and the margin trajectory improves, the market may eventually reprice the stock. But as of now, the evidence is promising yet unproven.